November 5, 2019

Mark A. Goldsmith
Chief Executive Officer
Revolution Medicines, Inc.
700 Saginaw Drive
Redwood City, CA 94063

       Re: Revolution Medicines, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted October 31, 2019
           CIK No. 0001628171

Dear Dr. Goldsmith:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in our
October 16, 2019 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1

Prospectus Summary
Overview, page 1

1.     We note your revised disclosure on page 1 and throughout in response to
comment 1 that
       RMC-4630 is a potent and selective inhibitor of SHP2, "based on
preclinical evidence
       described in this prospectus." Please provide a summary of the
preclinical studies in the
       prospectus summary, including the range of results observed, a
description of how the test
       was conducted and the number of tests conducted. Similarly, on page 103,
please revise
       to include a summary of the preclinical study conducted with RMC-4530,
including the
       range of results observed, how the test was conducted and the number of
tests conducted.
 Mark A. Goldsmith
Revolution Medicines, Inc.
November 5, 2019
Page 2
Certain relationships and related party transactions
Transactions with Sanofi, page 174

2.       Please include the disclosure required by Item 404 of Regulation S-K
for the Quality
         Agreement and Clinical Supply Agreement with Sanofi, including the
approximate dollar
         value of the amount involved with these agreements.
        You may contact Sonia Bednarowski at 202-551-3666 or Dietrich King at
202-551-8071
if you have questions regarding comments on the financial statements and
related
matters. Please contact Bonnie Baynes at 202-551-4924 or Lisa Vanjoske at
202-551-3614 with
any other questions.



FirstName LastNameMark A. Goldsmith                        Sincerely,
Comapany NameRevolution Medicines, Inc.
                                                           Division of
Corporation Finance
November 5, 2019 Page 2                                    Office of Life
Sciences
FirstName LastName